Chad Rogers is a serial entrepreneur with more than 20 years of experience in medical device technology, early stage startup management, and venture capital. Chad founded TypeZero Technologies, Inc. in 2013 and has led several successful startups throughout the course of his career as an investor, consultant, and corporate executive. In 2018, TypeZero was acquired by medical device company Dexcom (DXCM), a leader in continuous glucose monitoring technology.
Chad began his career as an investment banker for Harris Williams & Co. in Richmond, VA. He migrated to Silicon Valley where he joined InterTrust Technologies (ITRU) as the as Director of Corporate Development. InterTrust Technologies went public in 1999 and was later acquired by a joint venture owned by Sony and Phillips. Chad also held a senior role in a startup focused on interactive TV infrastructure, Axiomatic. Later, he served as CFO and Director of Strategic Planning for Aliph/Jawbone – the former consumer technology and noise abstraction algorithm company – where he led all day-to-day financial and operational activities. Prior to founding and serving as CEO of TypeZero, Chad served as CEO of the medical device company Hemosonics that was focused on using ultrasound radiation force to rapidly diagnose coagulation disorders in a point of care diagnostic. Chad has also held senior management roles in early stage startups including AMP3D and the Global Emergency Group. He also led San Francisco-based Fundamental Capital, a growth capital and private equity firm from 2005-2009 as Vice President and currently serves as Managing Director of Maywick Capital.
- M.B.A., University of California, Berkeley, Walter A. Haas School of Business
- B.A., University of Virginia, McIntire School of Commerce